Skip to main content

Advertisement

Log in

Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The objective of this study was to evaluate the initial response to treatment and the long-term outcome of patients with papillary thyroid cancer (PTC), according to the modified 2014 risk of recurrence classification of the American Thyroid Association and the presence or absence of insulin resistance (IR). We retrospectively reviewed our database of 636 records and selected 171 patients in whom we had previously validated the ATA risk of recurrence (RR) classification. From these patients, 38 non-diabetic subjects were included for analysis according to the following criteria: age older than 18 years, classic papillary thyroid carcinoma, stable body mass index 5 years previous to PTC diagnosis and during the entire time of follow-up, low and intermediate RR, follow-up after initial treatment at least for 3 years, and absence of any drug treatment for the metabolic syndrome. The IR was evaluated through the homeostasis model assessment (HOMA) index. When equal or higher than 2.5, patients were considered as harboring IR. The initial response to treatment was classified as remission or persistent disease (biochemical and/or structural). The clinical status at final follow-up was defined as no evidence of disease, biochemical persistent disease, structural persistent disease, or recurrence (biochemical or structural disease identified after a period of no evidence of disease). RR was as follows: low: n = 15, intermediate: n = 23. The median follow-up of this patient cohort was 5.5 years (range 3–22 years). We found no statistically significant differences when the response to initial treatment was considered in low-risk patients with or without IR. However, remission was more frequently found in those patients without IR when the intermediate RR was considered (36 vs. 11 %, p = 0.01). When considering the status at final follow-up, we found more frequency of structural persistent disease in both, low and intermediate RR patients with IR (10 vs. 0 %, p = 0.02 and 45 vs.7 %, p = 0.01, respectively). In this series of patients with PTC, the state of IR was associated with increased frequency of structural persistent disease at final follow-up. The IR could have a deleterious effect on the outcome of patients with PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008)

    Article  PubMed  Google Scholar 

  2. K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45, 362–364 (2014)

    Article  CAS  PubMed  Google Scholar 

  3. K. Esposito, P. Chiodini, A. Capuano, G. Bellastella, M.I. Maiorino, C. Rafaniello, D.B. Panagiotakos, D. Giugliano, Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44, 634–647 (2013)

    Article  CAS  PubMed  Google Scholar 

  4. L.G. Morris, D. Myssiorek, Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am. J. Surg. 200, 454–461 (2010)

    Article  PubMed Central  PubMed  Google Scholar 

  5. L. Davies, H. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)

    Article  CAS  PubMed  Google Scholar 

  6. A.Y. Chen, A. Jemal, E.M. Ward, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115, 3801–3807 (2009)

    Article  PubMed  Google Scholar 

  7. L. Enewold, K. Zhu, E. Ron, A.J. Marrogi, A. Stojadinovic, G.E. Peoples, S.S. Devesa, Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol. Biomark. Prev. 18, 784–791 (2009)

    Article  Google Scholar 

  8. G. Danaei, M.M. Finucane, J.K. Lin, G.M. Singh, C.J. Paciorek, M.J. Cowan, F. Farzadfar, G.A. Stevens, S.S. Lim, L.M. Riley, M. Ezzati, Global burden of metabolic risk factors of chronic diseases collaborating group (blood pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 377, 568–577 (2011)

    Article  PubMed  Google Scholar 

  9. T. Pappa, M. Alevizaki, Obesity and thyroid cancer: a clinical update. Thyroid 24, 190–199 (2014)

    Article  CAS  PubMed  Google Scholar 

  10. J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomniszcze, Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 18, 461–464 (2008)

    Article  PubMed  Google Scholar 

  11. S. Ayturk, A. Gursoy, A. Kut, C. Anil, A. Nar, N.B. Tutuncu, Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild to moderate iodine deficient area. Eur. J. Endocrinol. 161, 599–605 (2009)

    Article  CAS  PubMed  Google Scholar 

  12. J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomiszcze, Increase prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab. Syndr. Relat. Disord. 7, 375–380 (2009)

    Article  PubMed  Google Scholar 

  13. F. Balkan, E.D. Onal, U. Alper, D. Tuzun, D. Ozdemir, S.S. Inancli, R. Ersoy, B. Cakir, Is there any association between insulin resistance and thyroid cancer?: a case control study. Endocrine 45, 55–60 (2014)

    Article  CAS  PubMed  Google Scholar 

  14. A. Gursoy, Rising thyroid cancer incidence in the world might be related to insulin resistance. Med. Hypotheses 74, 35–36 (2009)

    Article  PubMed  Google Scholar 

  15. M.T. Goodman, L.N. Kolonel, L.R. Wilkens, The association of body size, reproductive factors and thyroid cancer. Br. J. Cancer 66, 1180–1194 (1992)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. C.M. Kitahara, E.A. Platz, L.E. Freeman, A.W. Hsing, M.S. Linet, Y. Park, C. Schairer, A. Schatzkin, J.M. Shikany, A. Berrington de González, Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol. Biomarkers Prev. 20, 464–472 (2011)

    Article  PubMed Central  PubMed  Google Scholar 

  17. Z.G. Zhao, X.G. Guo, C.X. Ba, W. Wang, Y.Y. Yang, J. Wang, H.Y. Cao, Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J. Int. Med. Res. 40, 2041–2050 (2012)

    Article  CAS  PubMed  Google Scholar 

  18. H.J. Kim, N.K. Kim, J.H. Choi, S.Y. Sohn, S.W. Kim, S.M. Jin, H.W. Jang, S. Suh, Y.K. Min, J.H. Chung, S.W. Kim, Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin. Endocrinol. 78, 134–140 (2013)

    Article  Google Scholar 

  19. A. Harari, B. End, S. Nishimoto, P.H. Ituarte, M.W. Yeh, Risk of advanced papillary thyroid cancer in obese patients. Arch. Surg. 147, 805–811 (2012)

    Article  PubMed  Google Scholar 

  20. J.E. Paes, K. Hua, R. Nagy, R.T. Kloos, D. Jarjoura, M.D. Ringel, The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J. Clin. Endocrinol. Metab. 95, 4244–4250 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Outcomes of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23, 1401–1407 (2013)

    Article  PubMed  Google Scholar 

  22. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)

    Article  PubMed  Google Scholar 

  23. G.W. Randolph, Q.Y. Duh, K.S. Heller, V.A. LiVolsi, S.J. Mandel, D.L. Steward, R.P. Tufano, R.M. Tuttle, American Thyroid Association Surgical Affairs Committee´s taskforce on thyroid cancer nodal surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22, 1144–1152 (2012)

    Article  PubMed  Google Scholar 

  24. Ito, A. Miyauchi, M. Kihara, K. Kobayashi, A. Miya. Prognostic values of clinical lymph node metastasis and macroscopic extrathyroid extension in papillary thyroid carcinoma. Endocr. J. 2014; [Epub ahead of print]

  25. F. Pitoia, L. Ward, N. Wohllk, C. Friguglietti, E. Tomimori, A. Gauna, R. Camargo, M. Vaisman, R. Harach, F. Munizaga, S. Corigliano, E. Pretell, H. Niepomnizcze, Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq. Bras. Endocrinol. Metabol. 53, 884–887 (2009)

    Article  PubMed  Google Scholar 

  26. R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)

    Article  CAS  PubMed  Google Scholar 

  27. F. Vaisman, A. Shaha, S. Fish, R.M. Tuttle, Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin. Endocrinol. 75, 112–119 (2011)

    Article  CAS  Google Scholar 

  28. M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441–446 (2011)

    Article  CAS  PubMed  Google Scholar 

  29. S. Bardet, E. Malville, J.P. Rame, E. Babin, G. Samama, G.D. De Raucourt, J.J. Michels, Y. Reznik, M. Henry-Amar, Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur. J. Endocrinol. 158, 551–560 (2008)

    Article  CAS  PubMed  Google Scholar 

  30. I.M. Cranshaw, B. Carnaille, Micrometastases in thyroid cancer. An important finding? Surg. Oncol. 17, 253–258 (2008)

    Article  PubMed  Google Scholar 

  31. S. Leboulleux, C. Rubino, E. Baudin, B. Caillou, D.M. Hartl, J.M. Bidart, J.P. Travagli, M. Schlumberger, Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J. Clin. Endocrinol. Metab. 90, 5723–5729 (2005)

    Article  CAS  PubMed  Google Scholar 

  32. C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)

    Article  CAS  PubMed  Google Scholar 

  33. R.H. Eckel, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome. Lancet 365, 1415–1428 (2005)

    Article  CAS  PubMed  Google Scholar 

  34. Z.T. Bloomgarden, Insulin resistance concepts. Diabetes Care 30, 1320–1326 (2007)

    Article  CAS  PubMed  Google Scholar 

  35. V. Vella, L. Sciacca, G. Pandini, R. Mineo, S. Squatrito, R. Vigneri, A. Belfiore, The IGF system in thyroid cancer: new concepts. Mol. Pathol. 54, 121–124 (2001)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. B. Tode, M. Serio, C.M. Rotella, G. Galli, F. Franceschelli, A. Tanini, R. Toccafondi, Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J. Clin. Endocrinol. Metab. 69, 639–647 (1989)

    Article  CAS  PubMed  Google Scholar 

  37. V. Vella, G. Pandini, L. Sciacca, R. Mineo, R. Vigneri, V. Pezzino, A. Belfiore, A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 87, 245–254 (2002)

    Article  CAS  PubMed  Google Scholar 

  38. R. Malaguarnera, F. Frasca, A. Garozzo, F. Gianì, G. Pandini, V. Vella, R. Vigneri, A. Belfiore, Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J. Clin. Endocrinol. Metab. 96, 766–774 (2011)

    Article  CAS  PubMed  Google Scholar 

  39. A. Belfiore, R. Malaguarnera, Insulin receptor and cancer. Endocr. Relat. Cancer 18, R125–R147 (2011)

    Article  CAS  PubMed  Google Scholar 

  40. S. Cinti, G. Mitchell, G. Barbatelli, I. Murano, E. Ceresi, E. Faloia, S. Wang, M. Fortier, A.S. Greenberg, M.S. Obin, Adipocyte death defines macrophage localization and functionin adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347–2355 (2005)

    Article  CAS  PubMed  Google Scholar 

  41. R. Cancello, C. Henegar, N. Viguerie, S. Taleb, C. Poitou, C. Rouault, M. Coupaye, V. Pelloux, D. Hugol, J.L. Bouillot, A. Bouloumie, G. Barbatelli, S. Cinti, P.A. Svensson, G.S. Barsh, J.D. Zucker, A. Basdevant, D. Langin, K. Clement, Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidlyobese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286 (2005)

    Article  CAS  PubMed  Google Scholar 

  42. L.K. Bachrach, F.R. Liu, G.N. Burrow, M.C. Eggo, Characterization of insulin-like growth factor-binding proteins from sheep thyroid cells. Endocrinology 125, 2831–2838 (1989)

    Article  CAS  PubMed  Google Scholar 

  43. V. Poulaki, C.S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D.A. Koutras, N. Mitsiades, Regulation of vascular endothelial growth factor expression by onsulin-like growth factor I in thyroid carcinomas. J. Clin. Endocrinol. Metab. 88, 5392–5398 (2003)

    Article  CAS  PubMed  Google Scholar 

  44. A. Belfiore, G. Pandini, V. Vella, S. Squatrito, R. Vigneri, Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81, 403–407 (1999)

    Article  CAS  PubMed  Google Scholar 

  45. R. Malaguarnera, A. Morcavallo, A. Belfiore, The Insulin and IGF-I pathway in endocrine glands carcinogenesis. J. Oncol. 2012, 635614 (2012)

    Article  PubMed Central  PubMed  Google Scholar 

  46. C.S. Fox, M.J. Pencina, R.B. D’Agostino, J.M. Murabito, E.W. Seely, E.N. Pearce, R.S. Vasan, Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch. Intern. Med. 168, 587–592 (2008)

    Article  PubMed  Google Scholar 

  47. E. Fiore, P. Vitti, P. Serum, TSH and risk of papillary thyroid cancer in nodular thyroid disease. J. Clin. Endocrinol. Metab. 97, 1134–1145 (2012)

    Article  CAS  PubMed  Google Scholar 

  48. D.S. McLeod, D.S. Cooper, P.W. Ladenson, K.B. Ain, J.D. Brierley, H.G. Fein, B.R. Haugen, J. Jonklaas, J. Magner, D.S. Ross, M.S.M.C. Skarulis, D.L. Steward, H.R. Maxon, Sherman For The National Thyroid Cancer Treatment Cooperative Study Group SI. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24, 35–42 (2014)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. M. Rivas, P. Santisteban, TSH-activated signaling pathways in thyroid tumorigenesis. Mol. Cell. Endocrinol. 213, 31–45 (2003)

    Article  CAS  PubMed  Google Scholar 

  50. K. Takada, N. Amino, H. Tada, K. Miyai, Relationship between proliferation and cell cycle-dependent Ca2+ influx induced by a combination of thyrotropin and insulin-like growth factor-I in rat thyroid cells. J. Clin. Invest. 86, 1548–1555 (1990)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. A. Ciampolillo, C. De Tullio, F. Giorgino, The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr. Med. Chem. 12, 2881–2891 (2005)

    Article  CAS  PubMed  Google Scholar 

  52. G. Milazzo, G.L. La Rosa, R. Catalfamo, R. Vigneri, A. Belfiore, Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. J. Cell. Biochem. 49, 231–238 (1992)

    Article  CAS  PubMed  Google Scholar 

  53. B.F.A.M. van der Laan, J.L. Freeman, S.L. Asa, Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5, 67–73 (1995)

    Article  PubMed  Google Scholar 

  54. J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomiszcze, Metformin treatment for small benign thyroid nodules in patients with insuline resistance. Metab. Syndr. Relat. Disord. 9, 69–75 (2011)

    Article  PubMed  Google Scholar 

  55. L. Wartofsky, Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision. Thyroid 19, 1139–1143 (2009)

    Article  PubMed  Google Scholar 

  56. S. Benvenga, Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 347–350 (2011)

    Article  CAS  PubMed  Google Scholar 

  57. J. Klubo-Gwiezdzinska, J. Costello, A. Patel, A. Bauer, K. Jensen, M. Mete, K.D. Burman, L. Wartofsky, V. Vasko, Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 98, 3269–3279 (2013)

    Article  CAS  PubMed  Google Scholar 

  58. G. Chen, S. Xu, K. Renko, M. Derwahl, Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 97, E510–E520 (2012)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fabián Pitoia.

Additional information

Hugo Niepomniszcze—in memoriam.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pitoia, F., Abelleira, E., Bueno, F. et al. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine 48, 894–901 (2015). https://doi.org/10.1007/s12020-014-0416-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0416-6

Keywords

Navigation